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Abstract 
Introduction: Colorectal cancer (CRC) is a common type of cancer with a relatively poor 
survival rate.  The survival rate of patients could be improved if CRC is detected early.  
Biomarkers associated with early stages of tumour development might provide useful tools 
for the early diagnosis of colorectal cancer. 
Area covered: Online searches using PubMed and Google Scholar were performed using 
keywords and with a focus on recent proteomic studies.  The aim of this review is to highlight 
the need for biomarkers to improve the detection rate of early CRC and provide an overview 
of proteomic technologies used for biomarker discovery and validation.  This review will also 
discuss recent proteomic studies which focus on identifying biomarkers associated with the 
early stages of CRC development. 
Expert opinion: A large number of CRC biomarkers are increasingly being identified by 
proteomics using diverse approaches.  However, the clinical relevance and introduction of 
these markers into clinical practice cannot be determined without a robust validation process.  
The size of validation cohorts remains a major limitation in many biomarker studies. 
Keywords: biomarker, colorectal cancer, diagnosis, early detection, proteomics, screening 
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1. Introduction 
CRC is a common type of malignancy which is the second leading cause of cancer 
related death in developed countries [1, 2].  The survival rate of CRC patients varies 
significantly based on the stage of the disease at the time of presentation.  The 5-year survival 
rate of CRC can be as high as 90% for patients with localised disease, declining to around 
70% for patients with regional metastasis and 15-20% for patients with distant metastasis [3].  
Therefore, improved survival rates could be achieved by detecting CRC early when treatment 
is more effective.  The detection of colorectal adenomas before the development of invasive 
malignancy may also significantly reduce the risk of CRC and related deaths [4, 5, 6].  
However, there is considerable molecular heterogeneity in the development and progression 
of CRC as multiple molecular pathways are involved [7].   
The early stages of CRC development are not often associated with specific 
symptoms, with some experiencing no symptoms at all [8].  Common symptoms associated 
with CRC include rectal bleeding, abdominal pain, weight loss and changes in bowel habit 
[9].  However, only a small minority of patients with these symptoms are diagnosed with 
CRC [10].  Therefore, population-based screening programs may help in reducing the risk 
and mortality rates of CRC in part by detecting and removing adenomas [11, 12].  Screening 
programmes generally rely on risk factors, usually age, to determine which individuals to 
screen [13].  However, the influence of screening programs for CRC on survival is still being 
debated [14, 15]. 
The main methods used in CRC screening programmes are faecal tests (e.g. guaiac- 
based faecal occult blood test (FOBT), immunochemical faecal occult blood tests (FIT) and 
faecal multi-DNA tests) and colorectal endoscopy (e.g. colonoscopy and/or flexible 
sigmoidoscopy).  Currently, lower gastrointestinal endoscopy is the optimal method of 
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detection and removal of colorectal adenomas.  According to a recent study, the risk of CRC 
can be reduced by 30% using a sigmoidoscopy based screening trial even though only the 
rectum and sigmoid colon are visualised by sigmoidoscopy [16].  However, colorectal 
endoscopy is invasive, relatively risky (e.g. colon perforation and anaesthetic complications) 
and expensive [17, 18].  Furthermore, a significant number of adenomas may be missed due 
to factors related to endoscopic procedure (observation technique of endoscopist, bowel 
preparation and colonoscopic insertion time) and adenoma (size, number, shape and 
anatomical location) [19, 20].  Another challenge is which adenomas should be 
removed/monitored since only a small proportion of adenomas progress to malignancy [21].  
Currently, the risk of malignant transformation is mainly determined by histopathological 
assessment of polyp size, degree of epithelial cell dysplasia and “villousness” [22].   
Faecal based tests are cheaper, less invasive and possibly more convenient than 
colorectal endoscopy.  However, the low specificity of the FOBT, the high number of false 
positives and associated follow-up colonoscopies have raised doubts over its clinical utility as 
a screening method [23].  The FIT addresses the main analytical problems associated with the 
FOBT since there is no need for repeated sampling, there are no dietary restrictions and it has 
a superior sensitivity [24].  Nevertheless, similar to FOBT, the performance of FIT is 
compromised by the presence of non-bleeding neoplasms and bleeding non-neoplastic 
conditions [25, 26].  Another clinically approved method for detecting CRC is multi-targeted 
DNA testing which detects altered DNA markers in cells shed into the stool.  Although this 
test has shown better sensitivity for detecting early CRC and adenomas compared with FIT, 
the specificity of DNA-based tests was inferior to that of FIT [27].  Therefore, non-invasive 
detection tools which identify high-risk adenomas and early carcinoma are still needed.  
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2. Proteomic biomarkers 
Proteomics describes a wide range of technologies used for large-scale identification, 
measurement, characterisation and analysis of proteins.  Proteomics can be classified into 
many branches based on the overall objective and technology of proteomic applications 
(Figure 1).  The majority of biomarker studies use quantitative mass spectrometry-based 
technologies for the identification and profiling of disease-associated or disease-specific 
protein markers.   
The detection and quantification of low-abundant proteins can be challenging in 
serum samples because of highly abundant and complex mixture of major proteins such as 
albumin and immunoglobulins [28].  However, the sensitivity of proteomics has significantly 
improved due to better sample preparation, advances in current technologies and the 
introduction of new ultrasensitive technologies such as single cell-quantum dot platform [29-
32].   
A biomarker refers to any measurable molecule that reflects normal or abnormal 
biological conditions [30].  Different types of molecules can be classified as biomarkers 
which can be evaluated in specific types of sample using different technologies (Figure 2).  
Biomarkers can be utilised in screening, diagnosis, prognosis, predicting therapy and 
monitoring the progression of CRC [33].  While mass spectrometry-based proteomics is 
mainly used for the discovery of a large number of protein targets, antibody-based techniques 
are generally essential for the validation of any potential biomarker targets [34-36]. 
 
3. Recent proteomic studies for the early detection of colorectal neoplasia 
Recent proteomic studies were evaluated in terms of assessed protein targets, 
proteomic methods, validation process, size and quality of sample cohorts, limitations and 
6 
 
potential clinical impact.  Based on this evaluation, individual studies were selected for 
discussion to highlight key findings and potential limitations.  The studies, their biomarker 
targets, proteomic technologies used, patient cohorts and commentary on study selection have 
been detailed in supplementary information Methods S1 and Table S1.  Blood-based samples 
(serum and plasma), tissue samples, urine and faecal samples and colorectal tumour models 
(animal models and organoid culture) will be reviewed.   
 
3.1. Blood-based biomarkers 
 Blood is potentially the ideal sample type for early detection markers since samples 
can be obtained in a straightforward manner at minimal cost, minimal risk and most 
importantly in a less-invasive manner compared to existing detection methods for example 
colonoscopy [18].  Moreover, standardised protocols for collecting and processing blood 
samples can easily be implemented. However, the detection of low abundance proteins 
remains a challenge. 
A potentially useful screening tool for early diagnosis of CRC is the identification of 
serum-based autoantibodies [37].  Tumour-associated autoantibodies are produced by the 
immune system as a reaction to the presence of abnormal molecules linked to the presence of 
a tumour, known as tumour-associated antigens (TAAs).  The identification of these 
molecules in serum samples is mainly achieved through proteomic-based technologies such 
as ELISA and protein microarrays [38].  For instance, eight TAAs, which were identified 
previously by protein microarray-based methods, were selected to test their combined ability 
to detect CRC by a multiplex beads assay using a well-characterised sample cohort 
containing 307 samples; 135 CRC (stage I=35, stage II=25, stage III=46 and stage IV=29), 
65 other cancer types, 14 inflammatory bowel disease and 93 healthy controls [39].  Out of 
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the eight TAAs, a panel of six TAAs (general transcription factor IIB, EGF-like repeats and 
discoidin I-like domains 3, HCK proto-oncogene, pim-1 proto-oncogene, serine/threonine 
kinase 4 and tumour protein P53) diagnosed CRC with 66% sensitivity at 90.0% fixed 
specificity [39].  Using a similar approach, a panel of tumour-associated autoantibodies (anti-
TP53, anti-IMPDH2, anti-MDM2 and anti-MAGEA4) detected early CRC with a sensitivity 
of 26% (95% CI, 13–45%) and advanced adenomas with a sensitivity of 20% (95% CI, 13–
29%) at a specificity of 90% [40].  The discovery cohort comprised of sera samples of 124 
healthy controls and 352 CRC (stage I=96, stage II=102, stage III=105 and stage IV=49) and 
the validation cohort included 100 healthy controls, 29 non-advanced adenomas, 99 advanced 
adenomas and 45 CRC (stage I=18, stage II=5, stage III=19 and stage IV=3) [40].  Although 
sensitivity of only 20% is a major limitation [40], both studies present a potentially useful 
approach whereby multiple TAAs or autoantibodies can be assessed simultaneously to detect 
early colorectal neoplasms [39, 40].  However, the main limitation in both studies was the 
size of patient cohorts used to validate the results.  There is still a need for additional 
validation using large and well-characterised cohorts.  Furthermore, the clinical utility of 
multiplex bead assays needs to be verified in external laboratories and needs to be compared 
to established screening tools before it can be considered for use in clinical practice.   
Selected/multiple reaction monitoring-mass spectrometry (S/MRM-MS) is 
increasingly used as a technology for validating preliminary proteomic discoveries.  For 
example, targeted multiplex MRM-MS assay was used to test a number of protein targets 
associated with early CRC [41].  The biomarker targets were identified by literature mining 
of publically available research data.  The MRM assay was optimised to enable the analysis 
of 187 protein targets using liquid chromatography mass spectrometry (LC-MS) [41].  The 
discovery cohort included 69 healthy controls and 69 CRC cases (stage I=13, stage II=35, 
stage III=15 and stage IV=6), while the validation cohort included 68 controls and 68 CRC 
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cases (stage I=16, stage II=35, stage III=14 and stage IV=3).  Stage I and II cases were 
detected with 91% overall accuracy using a protein panel that included 13 targets; alpha-1-
acid glycoprotein 1, alpha-1 antitrypsin, amylase alpha 2b, clusterin, complement c9 , enoyl-
CoA hydratase 1, ferritin light chain, gelsolin, osteopontin, selenium binding protein 1 , 
seprase, spondin 2 and tissue inhibitor of metalloproteinases 1 [41].   
The suitability of MRM/SRM targeted proteomics as a discovery and validation 
platform was confirmed by another study [42].  Different protein signature associated with 
early CRC (caeruloplasmin, serum paraoxonase/arylesterase 1, serpin peptidase inhibitor 
clade A, leucine-rich alpha-2-glycoprotein and tissue inhibitor of metalloproteinases 1) was 
identified in plasma samples using LC-MS and validated by SRM-MS [42].  To identify an 
optimal protein signature this study followed a detailed analytical approach; initial discovery 
by LC-MS, screening discovery by SRM-targeted MS, training and validation steps using 
SRM-MS and algorithmic analysis (the patient cohort used in each step is detailed in Table 
S1).  Both studies have shown that SRM/MRM can be used for testing multiple protein 
targets and may potential be a useful technology in the clinical practice [41, 42].  However, 
the detection accuracy of SRM assay using a protein biomarker signature was 72% [42] 
which was not superior to established CRC screening tests such as the FIT (around 80% 
detection accuracy) [43].  Furthermore, the clinical utility of MRM-based assay is still 
hindered by lack of standardisation, complex and laborious sample preparation, high cost, 
low sensitivity and peptide specificity [44].  Therefore, there is a need for further 
optimisation and validation of the findings using larger cohorts of participants.  
Evaluating multi-protein combinations is a strategy that is being increasingly used in 
many biomarkers studies.  Two potentially useful marker panels for the detection of CRC and 
advanced adenomas were identified and validated by ELISA using well-characterised patient 
cohort which included plasma samples of 150 CRC (stage I=34, stage II=51, stage III=34 and 
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stage IV=31), 151 advanced adenomas and 301 healthy controls [45].  The patient cohort was 
divided into equal discovery and validation cohorts.  Advanced adenomas were defined as “1 
or more of adenoma size ≥1 cm, sessile serrated polyp ≥1 cm, adenoma with ≥25% villous 
histologic features and adenoma with high-grade dysplasia”.  This study evaluated 28 
proteins which were identified as potential markers for early CRC in previous research using 
MRM-targeted MS as discussed above [41].  The optimum performance (diagnostic 
performance of around 82%) in detecting CRC was observed using a protein panel which 
included carcinoembryonic antigen, seprase, serpin A3, macrophage migration inhibitory 
factor, complement component 3, complement component 9, p-selectin glycoprotein ligand 1 
and cathepsin D [45].  Advanced adenomas were detected (diagnostic performance of around 
65%) using a panel of four proteins consisting of cathepsin D, clusterin, growth 
differentiation factor 15 and serum amyloid A1 [45].  Nevertheless, the validation cohort was 
not independent (i.e. internal validation) and included only a small number of samples.  
Furthermore, there was no rationale for the inclusion of advanced stage CRC as the main 
focus was the detection of early colorectal neoplasms.  Therefore, these findings require to be 
validated on larger independent patient cohorts comprised of early CRC cases.  
Inconsistencies in the findings of different proteomic studies are still being observed 
as highlighted by the following studies.  Using isobaric tag for relative and absolute 
quantitation-mass spectrometry (iTRAQ-MS), three serpin family proteins (serpin A1, serpin 
A3 and serpin C1) were identified as being differentially expressed in serum samples of CRC 
(stage I=2, stage II=2, stage III=4 and stage IV=7) and adenomas (n=15) compared to healthy 
controls (n=15) [46].  The results were confirmed by ELISA using serum samples of 21 
healthy controls and 19 CRC patients (stage I=2, stage II=5, stage III=5 and stage IV=7).  An 
increase in the serum levels of serpin A1 and serpin A3 were observed in CRC patients 
compared to healthy controls, whereas the level of serpin C1 was lower in CRC patients [46].  
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The diagnostic accuracy of these markers was 97% for serpin A1, 82% for serpin A3 and 
97% for serpin C1.  However, these findings are inconsistent with a previous study which 
measured serpin A3 by ELISA using plasma samples from 311 CRC patients (Dukes A=53, 
Dukes B=128, Dukes C=107 and Dukes D=23) and 359 healthy controls [47].  This study did 
not observe a significant change in the plasma level of serpin A3 in CRC patients compared 
to healthy controls.  Further analysis by immunohistochemistry on paired normal colon and 
CRC tissue samples (Dukes A=17, Dukes B=45, Dukes C=33 and Dukes=9) showed a 
decrease in the expression of serpin A3 in the early stages of CRC while it increased in the 
higher stages [47].  Similarly, the level of serpin A1 was associated with advanced stages of 
CRC, when analysed by immunohistochemistry using 522 CRC samples (lymph node stage: 
N0=278 and N1-2=244) [48].  Therefore, serpin A1 and serpin A3 proteins might not be 
suitable markers for the diagnosis of early CRC.  Furthermore, larger patient cohorts are 
needed for validating these preliminary proteomic findings. 
More robust findings may be achieved by using a combination of technologies for 
biomarkers discovery and validation.  Biomarker targets associated with CRC were also 
identified using a combination of proteomic (LC-MS) and metabolomic technologies (ultra-
high performance liquid chromatography (UHPLC-MS) and gas chromatography (GS-MS)) 
[49].  Pyruvate kinase isoenzyme type M2 (M2-PK), gamma enolase, serotonin and 14-3-3 
family members were all identified as potential markers for CRC detection.  The discovery 
cohort included plasma samples of 16 CRC patients (stage III=8 and stage IV=8) and 10 
healthy controls [49].  The results were confirmed by ELISA analysis using plasma samples 
from 40 CRC patients (10 for each stage), adenomas (n=20) and healthy controls (n=20).  
Moreover, immunohistochemical analysis of 14-3-3 epsilon (24 CRC tissue cores with 
corresponding normal) showed there was an increased expression of this protein in malignant 
tissue compared to normal colonic tissue.  Although this study presented interesting findings, 
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further validation is required because the sample size was small (n=40) especially for stage I 
and stage II CRC cases.  Additional investigation is especially needed for serotonin and 14-3-
3 proteins and gamma enolase, whereas the potential of M2-PK as a marker for detecting 
early CRC has been extensively studied [50, 51].   
An interesting biomarker candidate for the early detection of CRC is microtubule 
associated protein RP/EB family member 1 (MAPRE1) which has been identified in several 
studies [52-55].  A combination of LC-MS, antibody array (plasma samples: 60 healthy 
controls, 60 adenomas and 60 CRC) and immunohistochemistry assessment of fixed tissues 
(20 healthy controls, 10 adenomas and 66 CRC) was used to determine the association 
between MAPRE1 and early CRC (Table S1) [52].  The expression of MAPRE1 was found 
to be higher in both adenoma and CRC when compared to healthy controls.  Furthermore, a 
combination of MAPRE1 with carcinoembryonic antigen and adenylate kinase 1, tested by 
antibody array, revealed promising results in diagnosing adenoma and early CRC [52].  The 
increased levels of MAPRE1 (in tissues and plasma) and the relationship between this marker 
and early CRC have been previously reported in several studies [53-55].  Nevertheless, 
additional investigation of the role of MAPRE1 in the early stages of CRC development is 
required. 
 
3.2. Tissue-based biomarkers 
Tissue samples can be a useful platform for discovery and initial validation of novel 
biomarkers because large cohorts of well characterised tissue samples are readily available 
[56].  Moreover, formalin fixed tissue samples have become increasingly more suitable for 
proteomic analysis because of advances in proteomics especially improvements in the 
extraction of proteins from formalin fixed wax embedded tissue samples [57].   
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 Protein markers associated with early CRC were identified by LC-MS based 
proteomics using fixed tissue samples consisting of 36 CRC (pT1N0=16 and pT2N0=20), 20 
normal colon samples and 20 diverticulitis inflammatory controls [58].  The validation by 
immunohistochemistry was performed using 20 healthy controls, 20 diverticulitis controls, 20 
low grade adenomas, 20 high grade adenomas and 100 CRC (pT1N0=20, pT2N0=20, 
pT3=20 and pT4=20).  Half of the pT3 and pT4 samples had lymph node metastasis and four 
samples had metastasis to other organs.  The results showed that there was a significant 
increase in expression of kininogen-1, transport protein Sec24C and olfactomedin-4 in the 
early stages of CRC compared to that of normal and inflammatory tissues [58].  A similar 
trend towards increased expression (mainly weak and moderate immunostaining) was also 
observed in high-grade adenomas compared to lower grade adenomas and normal tissues.  
This study has therefore identified three markers associated with early CRC and has shown 
that fixed tissue sample can be a valuable source for proteomic discovery studies.  The 
increased expression of transport protein Sec24C in early CRC is a novel finding that 
necessitates further investigation.  The other two markers, olfactomedin-4 and kininogen-1, 
have been previously implicated in early CRC [59, 60].  The increased expression of 
olfactomin-4 in early CRC was detected in a previous study using proteomic-based analysis 
(iTRAQ labelling and matrix assisted laser desorption ionization time-of-flight (MALDI-
TOF/TOF- MS)) of tissue samples [59].  The proteomic findings were validated by 
immunohistochemistry on 30 adenomas and 84 CRC (stage I=26, stage II=14, stage III=25 
and stage IV=19).  Hence, olfactomedin-4 might be a potential candidate for early detection 
of CRC especially since it is also secreted [61].  Similarly, serum levels of kininogen-1 were 
analysed using MALDI-TOF/TOF-MS and validated by ELISA and immunohistochemistry 
[60].  The results indicated kininogen-1 might be a useful marker for the early detection of 
CRC with a diagnostic accuracy of around 66%-70% [60].  This is consistent with previous 
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research, which indicated that the level of kininogen-1 was higher in advanced adenomas and 
carcinomas compared to healthy samples [62].  Although promising, further investigation and 
validation of the role of olfactomedin-4 and kininogen-1 in early carcinoma are still needed 
since little is known about their roles in CRC.  
 In addition to fixed tissue, fresh-frozen tissue samples are often used in proteomics.  
A significant change in the expression of five proteins (S100 calcium-binding protein A9 
(S100A9), annexin A3, nicotinamide phosphoribosyltransferase, carboxylesterase 2 and 
calcium activated chloride channel A1) was detected in CRC tissues when compared to 
normal colonic tissues [63].  The biomarker targets were identified by performing iTRAQ-
MS on 24 fresh-frozen tumour tissues with corresponding normal tissues and by gene 
microarray analysis of 52 pairs of normal and tumour tissues (stage I=4, stage II=17, stage 
III=27 and stage IV=4).  The results were validated by immunohistochemistry using 18 pairs 
of fixed normal and tumour tissues (stage I=2, stage II=6, stage III=9 and stage IV=1) and by 
ELISA using serum samples from 76 healthy controls and 100 CRC cases (stage I=12, stage 
II=38, stage III=25 and stage IV=25).  The serum levels of S100A9 and annexin A3 were 
significantly higher in CRC patients compared to healthy controls.  This is consistent with a 
recent paper which reported that S100A9 was upregulated in CRC tissues [64].  Furthermore, 
S100A9 showed a promising performance in differentiating CRC patients from healthy 
controls (75% sensitivity) by ELISA using 60 serum samples (40 CRC cases and 20 
controls) [65].  There is a limited literature on the role of annexin A3 in early stages of CRC 
development, although there have been many previous reports on the potential role of other 
annexins (e.g. annexin A2, annexin A4, annexin A5) in tumour development, drug resistance, 
therapy and prognosis [66-68].  Nonetheless, a likely limitation of the study by Yu, Li and 
co-workers [63] was the size of validation cohort (76 controls and 100 CRCs).  A further 
limitation in the cohort used for ELISA validation was the significant difference in age 
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between healthy controls (median age=50 years old) and CRC patients (median age=61 years 
old).  Therefore, although this study presented an effective approach utilising both proteomics 
and genomics for the identification of protein biomarkers, there is still a requirement to 
validate the results using much larger cohorts.  Additionally, functional assessment of these 
proteins in the pathogenesis of CRC is also required. 
Biomarkers can also be identified by iTRAQ-LC-MS analysis of cancer-associated 
fibroblasts obtained from tumour tissues and corresponding normal tissues (n=12) [69].  The 
results were validated by IHC on 121 colon cancer tissues (stage I=31, stage II=53, stage 
III=9 and stage IV=28), quantitative PCR on 70 colon cancer samples (stage I=8, stage II=26, 
stage III=22 and IV=14) and using external gene expression datasets (GSE17538, 232 colon 
cancers (information about tumour stage not stated); GSE33113, 90 stage II colon cancers 
and GSE12945, 21 stage III colon cancers) [69].  Lysyl oxidase-like 2 (LOXL2) was 
identified as a promising biomarker for risk classification in early stage CRC patients [69].  
LOXL2 was also associated with survival and recurrence, and demonstrated predictive value 
for adjuvant therapy in stage II colon cancer.  Although the main focus was on identifying 
prognostic markers, the study presented a valuable approach for proteomic analysis of 
fibroblasts from the stromal compartment of tumours [69].  
 
3.3. Faecal and urine-based biomarkers 
 Urine and faeces are potentially useful samples for early detection markers since they 
can be obtained in a straightforward and non-invasive manner.  Nonetheless, the availability 
of large and well-characterised patient cohorts may be lacking compared to tissue-based 
samples.  
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 Faecal M2-PK is one of the most promising marker for early detection of CRC.  
According to a meta-analysis of eight clinical studies including 2,654 participants, the M2-
PK test demonstrated a pooled sensitivity of 79% and specificity of 80% [70].  However, the 
main limitations of studies included in the meta-analysis were a significant number of false 
positives in some studies, lack of standardisation in cut-off values, selection bias of 
participants and heterogeneity of patient/participant cohorts.  Moreover, the sensitivity of the 
M2-PK test for adenomas is still debatable [71].  Therefore, to accurately assess the potential 
of M2-PK as a marker for early CRC, the diagnostic performance of M2-PK need to be 
evaluated using a large screening population. 
 Clinically useful markers can also be identified in urine samples using mass 
spectrometry technology.  A recent study showed there was a relationship between high-risk 
adenomas and the levels of prostaglandin metabolites (PGE-M) which was measured using 
LC-MS [72].  The patient cohort comprised of 420 healthy control patients, 130 low-risk 
adenoma patients and 290 high-risk adenoma patients.  This finding is consistent with other 
proteomic studies that examined urinary PGE-M using the same analytical method [73, 74].  
Nevertheless, further validation of the results is still required since PGE-M is implicated in 
other malignancies and is also associated with a number of other inflammatory conditions 
[75].  Furthermore, since the study by Bezawada and co-workers [72] did not include CRC 
samples, evaluation of PGE-M in CRC samples is needed. 
3.4. Colorectal tumour models 
 Obtaining sequential clinical samples of tumour at intervals reflecting the progression 
of colorectal neoplasm is generally not considered ethical. Although analysis of other types of 
biological samples (e.g. blood, urine and faeces) obtained serially from patients with 
colorectal neoplasia maybe possible.  Therefore, tumour models, especially in vivo models, 
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offer an opportunity for dynamic characterisation of the molecular changes that occur in 
various stages of tumour development.  
The proteome and transcriptome profiles of fourteen organoids (7 colorectal tumours 
and 7 healthy controls) derived from seven patients were analysed using LC-MS and 
Affymetrix Human Gene 2.0 ST arrays [76].  Organoids were cultured in special medium 
after colonic crypts were isolated from surgically resected tissues of untreated colorectal 
cancer patients.  Data analysis showed 78 proteins were upregulated and 227 were 
downregulated in tumour organoids compared to healthy ones, although only 22 proteins 
showed similar expression profiles at the transcript level (the proteins are listed in Table S1) 
[76].  In another study, quantitative LC-MS analysis of membrane-enriched protein 
fractions derived from colonic organoids identified tyrosine pseudokinase (PTK7) as a 
marker associated with self-renewal and re-seeding capacity of colonic stem cells (Table S1) 
[77].  This indicates that organoids could be a useful in vitro model which facilitates 
biomarker discovery through manipulation and analysis of tumour at different stages of 
development.  Furthermore, a personalized patient-specific organoid proteome profile can be 
used to better understand the early molecular changes in CRC.  Future studies may yield 
promising findings especially if a larger number of organoids representing different stages of 
CRC development (normal colonic epithelium, adenoma and early carcinoma) are included in 
the analysis.  However, further verification of the suitability of this model is necessary 
considering the small number of organoids used.  Moreover, validation of the results using 
clinical samples is needed as the organoids are cultured in a medium (rich in growth factors) 
different from the in vivo microenvironment of tumour.  The laboratory processing time of 
colonic crypts is a key factor which can significantly change the RNA and protein expression 
profiles of tissues [78].     
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 Protein markers associated with early stages of CRC progression have been also 
identified by proteomic analysis of a CRC mouse model (Apc multiple intestinal neoplasia (min)/+, a 
nonsense mutation of the adenomatous polyposis coli (APC) gene) [79].  APCmin/+ mice and 
wild type mice of 8, 13, 18 and 22 weeks old were sacrificed for proteomic analysis.  Tumour 
interstitial fluids and sera from the mice were analysed by iTRAQ-MS and verified by 
targeted MRM-MS [79].  The results indicated that the early stages of CRC development 
were associated with a significant increase in the levels of six serine proteases 
(chymotrypsin-like elastase 1 (CELA1), chymotrypsin-like elastase 2A (CEL2A), 
chymotrypsinogen B (CTRB1), trypsin 2 (TRY2), trypsin 4 (TRY4) and chymotrypsin like 
(CTRL)) [79].  The increased levels of these proteins in CRC was confirmed by MRM assay 
using sera of CRC patients (n=30) and healthy individuals (n=30).  The combination of 
CELA1 and CTRL detected CRC with 90% sensitivity and 80% specificity.  The 
overexpression of CELA1 and CTRL in CRC was also confirmed by immunohistochemistry 
on tissue microarray comprising 80 pairs of CRC tissues (majority of CRCs were stage II and 
stage III, Table S1) and corresponding normal tissues.  Therefore, this study has presented a 
robust approach whereby novel protein markers associated with early CRC can be identified 
using tissue interstitial fluids.  However, further investigation of the roles of serine proteases 
in early CRC is necessary since only a small number of clinical samples were used to validate 
the results.  The serine proteases are members of a large family of proteolytic enzymes which 
have been implicated in tumour invasion and metastasis through their roles in digestion and 
cleavage activity of proteins such as matrix proteins [80, 81].   
 Tissue and faecal samples from CRC animal models could also be used to identify 
new biomarkers paving the way for subsequent validation on corresponding human samples 
[82].  For example, a number of proteins, including haemoglobin, haptoglobin, hemopexin, 
alpha-2-macroglobulin and cadherin-17, were identified by nanoflow reversed-phased LC–
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MS/MS analysis of faecal samples from APCmin mouse [83].  However, validation of the 
results using human samples remains essential.   
 
4. Conclusions 
There is still a need for sensitive, easily measured, reliable and cost-effective 
biomarkers for the early diagnosis of CRC.  Proteomics is generating a rich database for 
potential biomarkers that are refining our understanding of important molecular pathways 
involved in the early stages of CRC development.  However, it is still unclear when or if any 
of these targets will be translated into clinically useful tools for the early detection of CRC. 
 
5. Expert Commentary 
A major limitation in many proteomic studies is the small number of samples used in 
validating the results.  The use of large, well-characterised and statistically adequately 
powered patient cohorts is essential for robust validation.  Another potential limitation 
observed in a large number of studies was the composition of both the discovery and 
validation cohorts.  Although the inclusion of advanced CRC cases can be useful, the focus of 
early biomarker studies should be on adenomas and stage I and stage II CRCs. 
The analysis of controls versus early neoplasm samples is typically essential to the 
discovery and validation of early detection biomarkers.  Therefore, the findings of biomarker 
studies can be influenced by the method of selecting and clinically classifying control 
samples (e.g. self-reported asymptomatic individuals or individuals with normal 
colonoscopy).   
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A significant proportion of studies have identified protein targets and recommended 
them as markers for early detection of CRC mainly based on two criteria; the markers were 
differentially expressed in CRC compared to normal colonic mucosa and they had a 
reasonable diagnostic accuracy.  However, few studies have actually compared the 
performances of markers with existing screening tests (e.g. FOBT).  For markers to have the 
potential of being introduced to clinical practice, their performance should be at least non-
inferior and ideally superior to existing screening tools.  
Although similar proteomic technologies are used, different proteins are frequently 
being identified as potential biomarkers for the same disease.  This may be attributed to 
variations in processing of samples, size and quality of sample cohorts, type of samples, 
analytical platforms, data processing and interpretation methods [84, 85].  The reproducibility 
of proteomics could be enhanced if studies follow a standardised experimental approach and 
adhere to best practice guidelines.  Moreover, the introduction of automated algorithms for 
data analysis and quality control will further improve the consistency of proteomic results 
[86, 87].   
Although genomics and transcriptomics have been a major platform for biomarker 
discoveries, protein biomarkers are still necessary because they provide reflection on the 
physiological state of the cell and the phenotype of particular diseases [30].  Integration of 
genomics and proteomics data can provide better characterisation and understanding of the 
molecular events underlying CRC development and progression and this is reflected in the 
consensus molecular subtypes classification [7].  CRC develops through multiple pathways 
which contribute to the significant clinical variability between patients [7].  Therefore, a 
single biomarker is unlikely to have sufficient sensitivity or specificity for use as a screening 
tool for CRC [88].  Combining biomarkers could improve their clinical discriminative and 
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diagnostic value synergistically.  This is reflected by the increasing number of proteomic 
studies which have focused on biomarker panels rather than a single marker. 
The majority of proteomic technologies are still research-oriented and their precise 
relevance in clinical practice still needs to be established [89].  Nonetheless, new 
technologies such as SRM/MRM-MS and multiplex beads assays have shown a realistic 
translational capability [29].  For these assays to be incorporated in clinical practice, there is 
still a need for extensive assessment in multiple centres and where applicable these assays 
need to be compared to relevant clinically established assays (e.g. ELISA).   
 
Five-year view 
In the next few years, more protein biomarkers associated with early detection of 
CRC will be identified and validated by proteomics.  However, the clinical potential of 
markers will not be fully determined without significant improvements in the validation 
process.  New advancements in proteomic technologies may be integrated in studies of 
cancer-biomarkers.  The quality of biomarker discoveries possibly will improve as more 
studies will try to address problems in study design, sample preparation, size and quality of 
patient cohort and protocol standardisation.  Large and multidisciplinary research projects 
combining proteomics and other complementary technologies such as transcriptomics may 
become more common. 
Key issues 
• CRC is major disease with relatively high mortality rate. 
• The early detection of CRC may significantly improve the survival rate of CRC. 
• Protein biomarkers can be used as a screening tool to detect CRC at early stages. 
• Proteomics technologies enable the identification of a large number of protein 
biomarkers for early CRC detection. 
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• Many protein biomarkers have been identified in blood-based samples, tissue samples 
and cell lines. 
• Clinical and non-clinical samples (e.g. in vitro tumour models and animal tumour 
models) are used in proteomic analysis. 
• There are weaknesses in the validation process in a large number of proteomic 
studies. 
• Continued advancements in sample processing, detection technologies and 
computational analysis will gradually address the challenges in proteomics.  
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Figure legends 
Figure 1: Overview of proteomic technologies. Abbreviations: FRET, fluorescence resonance 
energy transfer; SPR, surface plasmon resonance; TAP-MS, tandem affinity purification-mass 
spectrometry; MALDI-TOF, matrix assisted laser desorption ionization time-of-flight; LC-
MS, liquid chromatography–mass spectrometry; S/MRM-MS, single/multiple reaction 
monitoring tandem mass spectrometry; iTRAQ, isobaric tags for relative and absolute 
quantitation; ICATs, isotope-coded affinity tags; TUBEs, tandem-repeated ubiquitin-binding 
entities; RPPA, reverse phase protein array; IHC, immunohistochemistry; ELISA, enzyme-
linked immunosorbent assay. 
 
Figure 2: Overview of screening biomarkers and their main aims in CRC, types of biomarker, 
methods of detection and types of bio-specimen. Abbreviations: IHC, immunohistochemistry; 
FISH, fluorescence in situ hybridization; HPLC, high-performance liquid chromatography; 
MALDI-TOF, matrix assisted laser desorption ionization time-of-flight; LC-MS, liquid 
chromatography-mass spectrometry; S/MRM-MS, single/multiple reaction monitoring 
tandem-mass spectrometry; DIGE, difference gel electrophoresis; PCR, polymerase chain 
reaction; ELISA, enzyme-linked immunosorbent assay. 
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Methods S1.  
Research criteria 
 PubMed and Google Scholar searches were performed using key words “biomarker, 
colorectal cancer, early colorectal cancer, early diagnosis, proteomics, proteome, screening”, within 
the title, abstract and/or text.  Only English language publications from 2014 onwards were selected 
(Table S1).  However, to discuss the findings of some of these studies reference has been made pre 
2014 studies.  References identified in retrieved articles were further screened for potentially 
relevant studies.  Only studies utilising clinical human samples in the discovery and/or validation 
phase were selected (the only exception to this was studies using organoid model, to highlight the 
potential of this new technology).  The full texts of selected articles were reviewed, and a decision 
on their eligibility for inclusion was then made based on; biomarker targets, proteomic 
technologies, study design, analytical approach, validation process, limitations and potential clinical 
impact.  Although there was no specific criterion for the size of patient cohorts, the focus was on 
studies with larger samples and better characterised .   
 
 
 
 
 
 
 
 
 Table S1.  Summary of proteomic studies, biomarker targets and their patient cohorts. 
Target(s) 
Discovery Validation 
Commentary Ref 
Method(s) Sample Method(s) Sample 
General transcription factor IIB, EGF-like repeats 
and discoidin I-like domains 3, HCK proto-
oncogene, pim-1 proto-oncogene, serine/threonine 
kinase 4 and tumour protein P53 
Targets were identified by previous studies 
using protein microarray-based methods 
Multiplex beads 
assay and 
ELISA 
Sera: 135 CRC (stage I=35, stage II=25, 
stage III=46 and stage IV=29), 65 other 
cancer types, 14 inflammatory bowel 
diseases and 93 healthy controls 
Illustrated the potential 
of autoantibodies as 
CRC markers, 
presented a useful assay 
for assessing biomarker 
panel and used a large 
and well-characterised 
patient cohort 
[39]   
Autoantibodies against tumour-associated antigens: 
inosine monophosphate dehydrogenase 2, MAGE 
family member A4, MDM2 proto-oncogene and 
tumour protein P53 
Multiplex 
serology, a 
fluorescent 
bead-based 
GST capture 
immunosorb
ent assay 
Sera: 124 normal and 352 
CRC (stage I=96, stage 
II=102, stage III=105 and 
stage IV=49) 
Multiplex 
serology, a 
fluorescent 
bead-based GST 
capture 
immunosorbent 
assay 
Sera: 49 CRC (high-grade dysplasia=4, 
stage I=18, stage II=5, stage III=19 and 
stage IV=3), 100 normal, 29 non-
advanced adenomas and 99 advanced 
adenomas 
Illustrated the potential 
of autoantibodies as 
CRC markers, 
presented a useful assay 
for assessing biomarker 
panel and used a large 
and well-characterised 
patient cohort 
[40] 
Alpha-1-acid glycoprotein 1, alpha-1 antitrypsin, 
amylase alpha 2b, clusterin, complement c9, enoyl-
coa hydratase 1, ferritin light chain, gelsolin, 
osteopontin, selenium binding protein 1, seprase, 
spondin 2 and tissue inhibitor of metalloproteinases 
1 
Targeted 
multiplex 
MRM-MS 
assay 
Plasma: 69 healthy controls 
and 69 CRC cases (stage I=13, 
stage II=35, stage III=15 and 
stage IV=6) 
Targeted 
multiplex 
MRM-MS assay 
Plasma: 68 controls and 68 CRC cases 
(stage I=16, stage II=35, stage III=14 and 
stage IV=3) 
Demonstrated the 
benefit of targeted MS 
as a validation 
technology for protein 
biomarker panel 
[41] 
Caeruloplasmin, serum paraoxonase/arylesterase 1, 
serpin peptidase inhibitor clade A, leucine-rich 
alpha-2-glycoprotein and tissue inhibitor of 
metalloproteinases 1 
LC MS/MS  
 
 
Targeted 
LC-MS 
(SRM)  
Discovery: tissues, 16 CRC 
(stage I=10, stage II=2, stage 
III=2 and stage IV=2) with 
adjacent normal mucosa 
 
Screening: plasma, 19 CRC 
(stage I=12, stage II=3, stage 
III=3 and stage IV=1) 
Targeted LC-
MS (SRM) 
Training: plasma: 23 non-advanced 
adenomas, 11 hyperplastic polyps, 66 
normal and 100 CRC (missing =3, stage 
I=32, stage II=26, stage III=31 and stage 
IV=8) 
Validation: plasma: 4 advanced 
adenomas, 2 benign adenomas, 1 
dysplastic polyp, 6 diverticular disease, 4 
Crohn, 50 healthy and 202 CRC (stage 
I=43, stage II=58, stage III=49 and stage 
IV=52) 
Demonstrated the 
potential of targeted 
MS as a validation tool 
and used a robust study 
design with patient 
cohorts reflecting 
different stages of CRC 
development  
[42] 
CRC detection panel: carcinoembryonic antigen, 
seprase, serpin A3, macrophage migration 
inhibitory factor, complement component 3, 
complement component 9, p-selectin glycoprotein 
ligand 1 and cathepsin D 
Adenoma detection panel: cathepsin D, clusterin, 
growth differentiation factor 15 and serum amyloid 
A1 
ELISA 
Plasma: 75 CRC (stage I=17, 
stage II=30, stage III=16 and 
stage IV=12), 75 advanced 
adenomas and 150 healthy 
controls 
ELISA 
Plasma: 75 CRC (stage I=17, stage 
II=21, stage III=18 and stage IV=19), 76 
advanced adenomas and 151 healthy 
controls 
Validated markers 
(identified by study 
above [41]) using 
clinically established 
assay (ELISA) 
[45] 
Serpin A1, serpin A3 and serpin C1 iTRAQ-MS 
Serum: 15 CRC (stage I=2, 
stage II=2, stage III=4 and 
stage IV=7) and 15 adenomas 
and 15 healthy controls  
ELISA 
Serum: 21 healthy controls and 19 CRC 
(stage I=2, stage II=5, stage III=5 and 
stage IV=7) 
Used a representative 
cohort, however small 
number of samples was 
used especially for 
stage I CRC 
[46] 
Pyruvate kinase isoenzyme type M2, gamma 
enolase, serotonin and 14-3-3 family members 
LC-MS/MS, 
UHPLC-MS 
and GC-MS 
 
Plasma: 16 CRC (stage III=8 
and stage IV=8) and 10 
healthy controls 
ELISA 
 
IHC (14-3-3 
epsilon) 
Plasma: 40 CRC (10 for each stage), 
adenomas (n=20) and healthy controls 
(n=20) 
24 CRC tissue cores with corresponding 
normal (tumour stage not provided) 
Multiple technologies 
were used to evaluate 
and validate promising 
CRC biomarkers, 
however patient cohorts 
were small 
[49] 
Microtubule-associated protein, RP/EB family, 
member 1 (MAPRE1) LC/MS-MS  
Plasma: 60 adenomas, 60 CRC 
(stage I= 11, stage II= 19, 
stage III= 21 and stage IV=9) 
and 60 healthy controls.  
Mouse model and cell lines  
Antibody array 
 
IHC 
Plasma: 60 adenomas, 60 CRC (stage 
I=11, stage II=19, stage III=21 and stage 
IV=9) and 60 healthy 
20 normal colonic tissues, 10 adenomas, 
and 66 CRC (tumour stage not provided) 
Interesting protein 
target with high 
potential, multiple 
technologies were used 
to evaluate and validate 
the results, although 
patient cohorts were 
small 
[52] 
Tissues-Based markers  
Kininogen-1, transport protein Sec24C and 
olfactomedin-4 LC-MS 
Fixed tissues of 36 early CRC 
(stage pT1N0=16 and stage 
pT2N0=20), 20 controls and 
20 diverticulitis inflammatory 
 
IHC 
Fixed tissues of 20 healthy controls, 20 
diverticulitis controls, 20 low grade 
adenomas, 20 high grade adenomas and 
112 CRC (high-grade dysplasia=12, 
stage pT1N0=20, stage pT2N0=20, stage 
pT3=20 and stage pT4=20) 
Kininogen is a 
promising target, 
highlighted the 
applicability of 
proteomics on fixed 
tissue and used patient 
cohorts reflecting 
different stages of CRC 
[58]   
S100 calcium-binding protein A9 (S100A9), 
annexin A3, nicotinamide 
phosphoribosyltransferase, carboxylesterase 2 and 
calcium activated chloride channel A1 
 iTRAQ-LC- 
MS 
 
Gene 
microarray, 
Affymetrix 
U133plus2.0 
24 pairs of fresh-frozen CRC 
(stage I=6, stage II=6, stage 
III=6 and stage IV=6) and 
normal tissues 
52 pairs of fresh-frozen CRC 
(stage I=4, stage II=17, stage 
III=27 and stage IV=4) and 
normal tissues 
  
ELISA 
 
 
IHC 
Serum:76 healthy controls and 100 CRC 
(stage I=12, stage II=38, stage III=25 and 
stage IV=25) 
 
18 pairs of CRC (stage I=2, stage II=6, 
stage III=9 and stage IV=1) and normal 
tissues 
Used multiple 
technologies and 
different sample types, 
but number of stage I 
CRCs was small  
[63] 
Lysyl oxidase-like 2  iTRAQ –LC-MS 
Cell lines: SW480, SW620, 
KM12C, and KM12SM 
 
 
Tissues: 12 matched colon 
cancer (stage: II=5 and stage 
III=7) 
 
 
PCR 
 
 
IHC 
 
 
Gene expression 
database 
Tissues: 70 colon cancer (stage I=8, stage 
II=26, stage III=22 and IV=14)   
 
Tissues: 121 colon cancer (stage I=31, 
stage II=53, stage III=9 and stage IV=28)  
 
Tissues: three external cohorts: 232 colon 
cancer (tumour stage was not provided), 
90 stage II colon cancers and 21 stage III 
colon cancers) 
Presented a robust 
model for assessing 
fibroblast-associated 
proteins using multiple 
technologies  
[69]   
Faecal and urine-based biomarkers  
Faecal pyruvate kinase isoenzyme type M2 (M2-
PK) Meta-analysis of eight clinical studies including 2,654 participants 
Highlighted the 
potential of faecal M2-
PK as a screening 
marker for early CRC 
[70] 
Prostaglandin E2 (PGE2) metabolite: 11 alpha-
hydroxy,9,15-dioxo-2,3,4,5-tetranor-prostane-1,20-
dioic acid 
LC/MS 
Urine: control=420, low risk 
adenoma=130 and high-risk 
adenoma=290   
NA NA 
One of the few 
proteomic studies that 
used urine samples 
from a large and well 
characterised cohort 
[72]  
Colorectal tumour models  
Synaptotagmin 7, ras-related protein rab-27b, 
coagulation factor iii, chloride intracellular channel 
5, kin of IRRE like, dual oxidase 2, 
carcinoembryonic antigen related cell adhesion 
molecule 7, mucin 12, v-set and immunoglobulin 
domain containing 2, microtubule associated 
protein 2, mucin 4, calpain 8, beta-1,3-
galactosyltransferase 5, macrophage stimulating 1 
receptor, myosin 1C , shroom family member 3, 
AHNAK, plastin 1, heparan sulfate proteoglycan 2, 
filamin binding lim protein 1 and dedicator of 
cytokinesis 5 and gelsolin 
LC-MS 
14 organoids: 7 CRC (stage 
not provided) and 7 healthy 
controls 
Affymetrix 
Human Gene 2.0 
ST arrays 
14 organoids: 7 CRC (stage not 
provided) and 7 healthy controls 
Illustrated the benefits 
of organoids as a CRC 
model for proteomic 
analysis and biomarker 
discovery in CRC 
[76] 
Protein tyrosine pseudokinase PTK7 Quantitative LC-MS 
3 organoids cultured in stem 
cell supporting medium versus 
3 organoids cultured in 
differentiation supporting 
medium (epidermal growth 
factor and Noggin [EN])  
CRC patients (stage not 
provided) 
IHC 
 
Quantitative 
real-time PCR 
1 normal human colonic mucosa 
 
2 organoids cultured in stem cell medium 
versus 2 organoids cultured in 
differentiation medium (epidermal 
growth factor and Noggin [EN]) 
 
Highlighted the 
benefits of organoids in 
biomarker discovery 
[77] 
Chymotrypsin-like elastase 1 (CELA1), 
chymotrypsin-like elastase 2A (CEL2A), 
chymotrypsinogen B (CTRB1), trypsin 2 (TRY2), 
trypsin 4 (TRY4) and chymotrypsin like (CTRL) 
iTRAQ-MS 
APCmin/+ mice and wild type 
mice of 8, 13, 18 and 22 weeks 
old 
Targeted MRM-
MS 
 
IHC (CELA1 
and CTRL) 
Sera 30 CRC (tumour stage: T2=4, 
T3=15 and T4=11, nodal stage: N0=15 
and N1-2=15) and 30 healthy individuals  
80 pairs of CRC tissues (tumour stage: 
T1=2, T2=12 and T3=39 and T4=27, 
nodal stage: N0=38 and N1-2=42) and 
corresponding normal tissues 
Used multiple 
technologies on 
different types of 
sample and presented a 
proteomic model for 
analysing tumour 
interstitial fluids 
[79]   
References are listed in the main manuscript.  Abbreviations: IHC, immunohistochemistry; ELISA, enzyme-linked immunosorbent assay; UHPLC-MS, Ultra high-performance 
liquid chromatography tandem mass spectrometry; LC-MS, liquid chromatography–mass spectrometry; iTRAQ, isobaric tags for relative and absolute quantitation; GC-MS, Gas 
Chromatography Mass Spectrometry; Targeted LC-MS (SRM/MRM), Targeted mass spectrometry based on selected/multiple reaction monitoring. 
 
 
 
 
